Suchergebnisse - "Personeni, Nicola"

PubPharm (116)

1

Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma

enthalten in: World journal of gastrointestinal oncology | 2023

von Dharmapuri, S. | Özbek, U. | Jethra, H. | +34

2

Trifluridine-Tipiracil and Bevacizumab in Refractory Metastatic Colorectal Cancer

enthalten in: The New England journal of medicine | 2023

von Prager, G. | Taieb, J. | Fakih, M. | +118

CommentIn: Nat Rev Clin Oncol. 2023 Aug;20(8):504. - PMID 37198414

3

Progression patterns and therapeutic sequencing following immune checkpoint inhibition for hepatocellular carcinoma : An international observational study

enthalten in: Liver international : official journal of the International Association for the Study of the Liver | 2023

von Talbot, T. | D'Alessio, A. | Pinter, M. | +33

CommentIn: Liver Int. 2023 Mar;43(3):528-530. - PMID 36808694

4

Neutrophil-to-Lymphocyte and Platelet-to-Lymphocyte Ratios as Prognostic Biomarkers in Unresectable Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab

enthalten in: Cancers | 2022

von Wu, Y. | Fulgenzi, C. | D'Alessio, A. | +32

5

Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma

enthalten in: Liver international : official journal of the International Association for the Study of the Liver | 2022

von Vithayathil, M. | D'Alessio, A. | Fulgenzi, C. | +32

CommentIn: Liver Int. 2022 Nov;42(11):2352-2353. - PMID 36162086

6

Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice : Results of the AB-real study

enthalten in: European journal of cancer (Oxford, England : 1990) | 2022

von Fulgenzi, C. | Cheon, J. | D'Alessio, A. | +34

7

Preliminary evidence of safety and tolerability of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma and Child-Pugh A and B cirrhosis : A real-world study

enthalten in: Hepatology (Baltimore, Md.) | 2022

von D'Alessio, A. | Fulgenzi, C. | Nishida, N. | +32

CommentIn: Hepatology. 2022 Oct;76(4):906-908. - PMID 35491442

8

Determinants of Treatment Benefit and Post-Treatment Survival for Patients with Hepatocellular Carcinoma Enrolled in Second-Line Trials after the Failure of Sorafenib Treatment

enthalten in: Journal of personalized medicine | 2022

von Personeni, N. | Pressiani, T. | Zanuso, V. | +10

9

Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas : An Early Exploratory Analysis

enthalten in: Targeted oncology | 2022

von Rimini, M. | Burgio, V. | Antonuzzo, L. | +13

10

Real-World Data on Ivosidenib in Patients with Previously Treated Isocitrate Dehydrogenase 1-Mutated Intrahepatic Cholangiocarcinomas: An Early Exploratory Analysis

enthalten in: Targeted oncology | 2022

von Rimini, M. | Burgio, V. | Antonuzzo, L. | +13

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[12]